Upcoming event

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

Take home message

We discovered ERBB2 missense mutation as a novel genomic biomarker of response to neoadjuvant platinum-containing chemotherapy. We also showed that the presence of ERCC2 mutation does not always confer sensitivity to platinum-based chemotherapy.

Publication: Eur Urol. 2015 Jan 27

PII: S0302-2838(15)00037-8

DOI: 10.1016/j.eururo.2015.01.014

The research for markers of therapeutic response could help us to individualize therapies in bladder cancer. In this work the authors studied a population of 71 patients submitted to neodjuvant chemotherapy and posterior radical cystectomy, and divided the on responders and non-responders based on final pathological report. By DNA-based technology, the authors concluded that ERBB2 mutations are a prognostic factor of good response to cisplatin base chemotherapy. Although this constitutes a very promising marker for selecting patients for NAC, further validation of their results is warranted in order to establish the reliability of their results.